Drug-diagnostic co-development: how to harness the value

Abstract

Some years ago, we developed a value assessment process that was predicated on certain assumptions about how valuation might be influenced by drug development and marketing factors. Here, we discuss how our assumptions have held up particularly in light of regulatory and reimbursement changes. In addition, we assess how the relationship models derived from the value-assessment process have been substantiated by reviewing some recent cases of testing and stratification.